Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We report a FAP-associated CMVPTC tumor with atypically aggressive features harboring a RAS mutation and review the molecular mechanisms associated with this interesting PTC subtype.
|
24702198 |
2014 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Rearranged during transfection (RET)/papillary thyroid carcinoma (PTC) gene rearrangements are one of the major genetic alterations found in papillary thyroid carcinoma.
|
24957039 |
2014 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We have developed a home-brew tetracolor break-apart probe able to simultaneously identify the 2 most common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants in papillary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular thyroid carcinoma.
|
24510380 |
2014 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Point mutations in the BRAF or RAS genes or rearranged in transformation (RET)/papillary thyroid carcinoma (PTC) gene rearrangements are observed in approximately 70% of papillary cancer cases.
|
23128507 |
2013 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Following identification of RET, it was found that somatic rearrangements of this gene, conventionally designated as RET/PTC, are frequently present in papillary thyroid carcinoma.
|
23461584 |
2013 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We did a comprehensive screen for 548 known and putative fusion genes in 27 samples of thyroid tumors and three positive controls-one thyroid cancer cell line (TPC-1) and two PTCs with known CCDC6-RET (alias RET/PTC1) fusion gene, using this microarray.
|
22961909 |
2012 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
German patients (n=253) with DTC (papillary thyroid carcinoma [PTC] and follicular thyroid carcinoma [FTC]) and HC (n=302) were genotyped for polymorphisms within the vitamin D metabolizing enzymes such as 25-hydroxylase (CYP2R1[rs12794714, rs10741657]), 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1[rs10877012, rs4646536]), and 25-hydroxyvitamin D 24-hydrolase (CYP24A1[rs927650, rs2248137, rs2296241]).
|
22690899 |
2012 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The list of putative biological and clinical factors that may influence the PTC gene expression profile is long, but there are sufficient data reported in the literature to link expression profiles with differing pathological variants of PTC.
|
21411301 |
2011 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These structural changes lead to the formation of fusion genes RET-PTC, TRK(-T), and BRAF-AKAP9, which originate as a result of intrachromosomal or interchromosomal rearrangements and are found in papillary thyroid carcinoma.
|
20951315 |
2010 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
|
20012784 |
2010 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Each case had a previous fine-needle aspiration diagnosis classified according to the British Thyroid Association Guidelines categorized as inadequate (Thy1) (n = 19), benign (Thy2) (n = 19), follicular lesion and follicular lesion with atypia (Thy3) (n = 109), suspicious of PTC (Thy4) (n = 29), or malignant (Thy5) (n = 11).
|
20950194 |
2010 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Given that XB130 is a thyroid-specific tyrosine kinase substrate, we asked whether it is targeted by RET/PTC, a genetically rearranged, constitutively active, thyroid-specific tyrosine kinase that plays a pathogenic role in papillary thyroid cancer.
|
19060924 |
2009 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation.
|
19495791 |
2009 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Preliminary results from our molecular oncology studies on adult-onset papillary thyroid cancer provide evidence for the induction of RET/PTC rearrangements and BRAF point mutation (both known to be early stage events in adult-onset papillary thyroid cancer) but with a difference: cases associated with the rearrangements were more frequent at high doses, and developed sooner than those with BRAF mutation.
|
18406659 |
2008 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The reduction in miR-146a led to less efficient inhibition of target genes involved in the Toll-like receptor and cytokine signaling pathway (TRAF6, IRAK1), and PTC1 (also known as CCDC6 or H4), a gene frequently rearranged with RET proto-oncogene in PTC.
|
18474871 |
2008 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We report the successful validation of a combined gene expression profiling and tissue microarray approach to papillary thyroid carcinoma (PTC) biomarker identification.
|
18261626 |
2008 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the methylation pattern of 17 gene promoters in nine thyroid cancer cell lines and in 38 primary thyroid carcinomas (13 papillary thyroid carcinoma [PTC], 10 follicular thyroid carcinoma [FTC], 9 undifferentiated thyroid carcinoma [UTC], 6 medullary thyroid carcinoma [MTC]), 12 goiters, and 10 follicular adenomas (FA) by methylation- specific polymerase chain reaction (PCR).
|
16889486 |
2006 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results indicated that RET/PTC may be useful as a specific molecular marker for papillary thyroid carcinomas.
|
16015630 |
2005 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Methylation-specific PCR analyses showed that SLC5A8 was methylated in 90% of PTC-cf. and in about 20% of other papillary thyroid carcinomas.
|
15687339 |
2005 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although ret/PTC rearrangements have been identified in both spontaneous and radiation-induced papillary thyroid cancer, they seem more frequent among radiation-associated tumors.
|
15126554 |
2004 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
|
15184868 |
2004 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.
|
14712216 |
2004 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas.
|
15356021 |
2004 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC rearrangements are believed to be tumor-initiating events in papillary thyroid carcinomas.
|
14555660 |
2003 |